CN101304736A - 治疗子宫内膜异位症的ikk抑制剂 - Google Patents

治疗子宫内膜异位症的ikk抑制剂 Download PDF

Info

Publication number
CN101304736A
CN101304736A CNA2006800414833A CN200680041483A CN101304736A CN 101304736 A CN101304736 A CN 101304736A CN A2006800414833 A CNA2006800414833 A CN A2006800414833A CN 200680041483 A CN200680041483 A CN 200680041483A CN 101304736 A CN101304736 A CN 101304736A
Authority
CN
China
Prior art keywords
substituted
aryl
nitrogen
alkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800414833A
Other languages
English (en)
Chinese (zh)
Inventor
S·S·帕尔默
S·纳塔拉雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA filed Critical Laboratoires Serono SA
Publication of CN101304736A publication Critical patent/CN101304736A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2006800414833A 2005-09-07 2006-08-28 治疗子宫内膜异位症的ikk抑制剂 Pending CN101304736A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71464505P 2005-09-07 2005-09-07
US60/714,645 2005-09-07
EP05109450.6 2005-10-11
EP05109450 2005-10-11
PCT/US2006/033686 WO2007030362A1 (en) 2005-09-07 2006-08-28 Ikk inhibitors for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
CN101304736A true CN101304736A (zh) 2008-11-12

Family

ID=37663766

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800414833A Pending CN101304736A (zh) 2005-09-07 2006-08-28 治疗子宫内膜异位症的ikk抑制剂

Country Status (10)

Country Link
US (1) US20100069387A1 (cg-RX-API-DMAC7.html)
EP (2) EP1931322B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009507073A (cg-RX-API-DMAC7.html)
KR (1) KR20080052650A (cg-RX-API-DMAC7.html)
CN (1) CN101304736A (cg-RX-API-DMAC7.html)
AU (1) AU2006287767B2 (cg-RX-API-DMAC7.html)
CA (1) CA2621057A1 (cg-RX-API-DMAC7.html)
EA (1) EA200800755A1 (cg-RX-API-DMAC7.html)
IL (1) IL189659A0 (cg-RX-API-DMAC7.html)
WO (1) WO2007030362A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101503402A (zh) * 2009-03-10 2009-08-12 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
CN119769990A (zh) * 2024-12-26 2025-04-08 大连医科大学附属第二医院 子宫内膜异位症的检测系统和治疗剂

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ, インコーポレイテッド Hdacおよび/またはcdk阻害剤としてのイミダゾシルピリジン化合物
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
CA2763786C (en) 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
ES2463826T3 (es) 2009-06-08 2014-05-29 Gilead Sciences, Inc. Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina
CN105132529A (zh) 2009-07-24 2015-12-09 吉第克生物技术有限公司 子宫内膜癌的标记物
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
WO2019169113A1 (en) * 2018-03-02 2019-09-06 Ponce Medical School Foundation, Inc. Compositions and methods for the treatment of endometriosis
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
DE10199028I2 (de) 1983-11-02 2004-07-01 Applied Research Systems Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit.
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
JP2002193938A (ja) * 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
CZ20032287A3 (cs) * 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003015820A1 (en) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. GnRH AGONIST COMBINATION DRUGS
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EP1670908A2 (en) * 2003-10-02 2006-06-21 Xantos Biomedicine AG Medical use of tbk-1 or of inhibitors thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101503402A (zh) * 2009-03-10 2009-08-12 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
CN101503402B (zh) * 2009-03-10 2014-06-25 沈阳药科大学 2-苯胺嘧啶衍生物及其制备和用途
CN119769990A (zh) * 2024-12-26 2025-04-08 大连医科大学附属第二医院 子宫内膜异位症的检测系统和治疗剂

Also Published As

Publication number Publication date
US20100069387A1 (en) 2010-03-18
EP2266561A3 (en) 2011-05-18
JP2009507073A (ja) 2009-02-19
EA200800755A1 (ru) 2008-10-30
KR20080052650A (ko) 2008-06-11
AU2006287767A1 (en) 2007-03-15
EP1931322A1 (en) 2008-06-18
EP1931322B1 (en) 2012-08-15
IL189659A0 (en) 2008-08-07
WO2007030362A1 (en) 2007-03-15
AU2006287767B2 (en) 2010-05-13
EP2266561A2 (en) 2010-12-29
CA2621057A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
EP1931322B1 (en) Ikk inhibitors for the treatment of endometriosis
TW201808297A (zh) 子宮內膜病症治療劑之用法及用量
US20080306057A1 (en) P13K Inhibitors for the Treatment of Endometriosis
US11446351B2 (en) Composition for treating one or more estrogen related diseases
HK1152647A (en) Ikk inhibitors for the treatment of endometriosis
US8658640B2 (en) JNK inhibitors for the treatment of endometriosis
MX2008002908A (es) Inhibidores de ikk para el tratamiento de endometriosis
BRPI0615700A2 (pt) uso de um inibidor ikk na fabricação de um medicamento para o tratamento e/ou prevenção de endometriose em um indivìduo
CN101300047A (zh) Pi3k抑制剂用于子宫内膜异位症的治疗
AU2006270184B2 (en) JNK inhibitors for the treatment of endometreosis
AU2011265521B9 (en) JNK inhibitors for the treatment of endometreosis
HK1119103A (zh) 治疗子宫内膜异位症的jnk抑制剂
HK1123234A (en) Pi3k inhibitors for the treatment of endometriosis
CN101262906A (zh) 治疗子宫内膜异位症的jnk抑制剂
KR20080052641A (ko) 자궁내막증 치료용 pi3k 억제제
JP2020114805A (ja) エストロゲン受容体α阻害作用を有するエストロゲン受容体βパーシャルアゴニストを用いた、子宮内膜症、子宮腺筋症等の婦人科疾患の疼痛、及び/又は器質的病変の治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: (2)[32]2005.10.11 [33]EP [31]05109450.6

False: (2)[32]2005.10.10 [33]EP [31]05109450.6

Number: 46

Page: 900

Volume: 24

CI02 Correction of invention patent application

Correction item: Priority

Correct: (2)[32]2005.10.11 [33]EP [31]05109450.6

False: (2)[32]2005.10.10 [33]EP [31]05109450.6

Number: 46

Page: The title page

Volume: 24

ERR Gazette correction

Free format text: CORRECT: PRIORITY; FROM: (2)(32)2005.10.10 (33)EP -(31)05109450.6 TO: (2)(32)2005.10.11 (33)EP -(31)05109450.6

ASS Succession or assignment of patent right

Owner name: MERCK SERONO CO., LTD.

Free format text: FORMER OWNER: SERONO LABORATORIES

Effective date: 20100318

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: VAUD, SWITZERLAND TO: COINSINS, SWITZERLAND

TA01 Transfer of patent application right

Effective date of registration: 20100318

Address after: Swiss Coyne Hince

Applicant after: Merck Serono S. A.

Address before: Swiss state

Applicant before: Serono Lab

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20081112